who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
Company profile
Ticker
ANIK
Exchange
Website
CEO
Joseph Darling
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANIKA RESEARCH INC, ANIKA THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Anika Securities, Inc. • Anika Therapeutics Limited • Anika Therapeutics S.r.l. • ArthroSurface Incorporated • Parcus Medical, LLC ...
IRS number
43145961
ANIK stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Mar 24
8-K
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
13 Mar 24
8-K
Departure of Directors or Certain Officers
26 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jan 24
S-8
Registration of securities for employees
19 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
2 Nov 23
8-K
Regulation FD Disclosure
21 Sep 23
S-8
Registration of securities for employees
8 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
Transcripts
ANIK
Earnings call transcript
2023 Q4
13 Mar 24
ANIK
Earnings call transcript
2023 Q3
2 Nov 23
ANIK
Earnings call transcript
2023 Q2
8 Aug 23
ANIK
Earnings call transcript
2023 Q1
9 May 23
ANIK
Earnings call transcript
2022 Q4
6 Mar 23
ANIK
Earnings call transcript
2022 Q3
9 Nov 22
ANIK
Earnings call transcript
2022 Q2
6 Aug 22
ANIK
Earnings call transcript
2022 Q1
7 May 22
ANIK
Earnings call transcript
2021 Q4
9 Mar 22
ANIK
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 70.65 mm | 70.65 mm | 70.65 mm | 70.65 mm | 70.65 mm | 70.65 mm |
Cash burn (monthly) | (no burn) | 1.43 mm | 2.56 mm | 2.54 mm | (no burn) | 412.08 k |
Cash used (since last report) | n/a | 9.83 mm | 17.61 mm | 17.51 mm | n/a | 2.84 mm |
Cash remaining | n/a | 60.83 mm | 53.04 mm | 53.14 mm | n/a | 67.81 mm |
Runway (months of cash) | n/a | 42.6 | 20.7 | 20.9 | n/a | 164.6 |
Institutional ownership, Q3 2023
87.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 115 |
Opened positions | 27 |
Closed positions | 29 |
Increased positions | 29 |
Reduced positions | 43 |
13F shares | Current |
---|---|
Total value | 240.73 bn |
Total shares | 12.98 mm |
Total puts | 800.00 |
Total calls | 900.00 |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Trigran Investments | 2.22 mm | $41.30 bn |
BLK Blackrock | 1.42 mm | $26.38 bn |
Caligan Partners | 1.08 mm | $20.15 bn |
Dimensional Fund Advisors | 860.14 k | $16.02 bn |
Vanguard | 767.80 k | $14.30 bn |
Boothbay Fund Management | 617.60 k | $11.51 bn |
Renaissance Technologies | 588.63 k | $10.97 bn |
Millennium Management | 574.54 k | $10.70 bn |
STT State Street | 338.67 k | $6.31 bn |
Acadian Asset Management | 336.06 k | $6.26 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Michael L Levitz | Stock Option Common Stock | Grant | Acquire A | No | No | 27.98 | 51,682 | 1.45 mm | 51,682 |
15 Mar 24 | Michael L Levitz | RSU Common Stock | Grant | Acquire A | No | No | 0 | 21,329 | 0.00 | 21,329 |
15 Mar 24 | David Colleran | Stock Option Common Stock | Grant | Acquire A | No | No | 27.98 | 46,875 | 1.31 mm | 46,875 |
15 Mar 24 | David Colleran | RSU Common Stock | Grant | Acquire A | No | No | 0 | 19,345 | 0.00 | 19,345 |
15 Mar 24 | Anne Nunes | Stock Option Common Stock | Grant | Acquire A | No | No | 27.98 | 26,442 | 739.85 k | 26,442 |
15 Mar 24 | Anne Nunes | RSU Common Stock | Grant | Acquire A | No | No | 0 | 10,912 | 0.00 | 10,912 |
15 Mar 24 | Blanchard Cheryl R | Stock Option Common Stock | Grant | Acquire A | No | No | 27.98 | 182,699 | 5.11 mm | 182,699 |
15 Mar 24 | Blanchard Cheryl R | RSU Common Stock | Grant | Acquire A | No | No | 0 | 75,395 | 0.00 | 75,395 |
11 Mar 24 | Blanchard Cheryl R | Common Stock | Payment of exercise | Dispose F | No | No | 25.79 | 14,534 | 374.83 k | 151,694 |
11 Mar 24 | Blanchard Cheryl R | Common Stock | Option exercise | Acquire M | No | No | 0 | 30,059 | 0.00 | 166,228 |
News
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $37
14 Mar 24
Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $22 Price Target
14 Mar 24
Anika Therapeutics: Q4 Earnings Insights
13 Mar 24
Anika Therapeutics Q4 2023 Adj EPS $0.05 Beats $(0.26) Estimate, Sales $42.971M Beat $41.405M Estimate
13 Mar 24
Anika Therapeutics Sees FY24 Revenue $168M-$173M Vs $179.42M Est.
13 Mar 24
Press releases
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
27 Feb 24
Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
13 Feb 24